Literature DB >> 28116930

Preparation and preservation of viable Akkermansia muciniphila cells for therapeutic interventions.

J P Ouwerkerk1, S Aalvink1, C Belzer1, W M De Vos1,2,3.   

Abstract

The anaerobic gut bacterium Akkermansia muciniphila is a well-characterised member of the mucosal microbiota and has shown to be a gut symbiont in human. A. muciniphila has been negatively associated with obesity and its associated metabolic disorders in various human cohorts while treatment with A. muciniphila cells reversed highfat diet-induced obesity and its associated metabolic disorders in mouse models. Therefore, administration of A. muciniphila has been suggested as a possible new therapeutic treatment for these omnipresent diseases. Here we describe a potentially scalable workflow for the preparation and preservation of high numbers of viable cells of A. muciniphila obtained from 1 l laboratory scale growth under strict anaerobic conditions for therapeutic interventions. This resulted in viable A. muciniphila cells with high yields and very high stability, with up to 97.9±4.5% survival for a time period of 1 year at -80 °C in glycerol-amended medium. Moreover, various quality assessment and control procedures were developed to ensure the use of viable cells of A. muciniphila. Several microscopic, culturing, and molecular approaches were applied to monitor the presence, abundance and recovery of A. muciniphila before, during, and after its administration to high-fat treated mice. We show that viable A. muciniphila cells can be recovered from caecal and colon content (up to 1×1010 cells/g), testifying for the efficiency of the described workflow.

Entities:  

Keywords:  delivery; laboratory scale production; stability; therapeutic microbe; viability

Mesh:

Year:  2017        PMID: 28116930     DOI: 10.3920/BM2016.0096

Source DB:  PubMed          Journal:  Benef Microbes        ISSN: 1876-2883            Impact factor:   4.205


  9 in total

Review 1.  Challenges in the production and use of probiotics as therapeuticals in cancer treatment or prevention.

Authors:  Alejandra Mejía-Caballero; Vianey Anahi Salas-Villagrán; Alaide Jiménez-Serna; Amelia Farrés
Journal:  J Ind Microbiol Biotechnol       Date:  2021-12-23       Impact factor: 4.258

2.  Genomic Evidence for Bacterial Determinants Influencing Obesity Development.

Authors:  Raphael D Isokpehi; Shaneka S Simmons; Matilda O Johnson; Marinelle Payton
Journal:  Int J Environ Res Public Health       Date:  2017-03-26       Impact factor: 3.390

3.  Safety Assessment of Lactobacillus helveticus KLDS1.8701 Based on Whole Genome Sequencing and Oral Toxicity Studies.

Authors:  Bailiang Li; Da Jin; Smith Etareri Evivie; Na Li; Fenfen Yan; Li Zhao; Fei Liu; Guicheng Huo
Journal:  Toxins (Basel)       Date:  2017-09-24       Impact factor: 4.546

Review 4.  Akkermansia and Microbial Degradation of Mucus in Cats and Dogs: Implications to the Growing Worldwide Epidemic of Pet Obesity.

Authors:  Jose F Garcia-Mazcorro; Yasushi Minamoto; Jorge R Kawas; Jan S Suchodolski; Willem M de Vos
Journal:  Vet Sci       Date:  2020-04-15

Review 5.  The Interaction of the Gut Microbiota with the Mucus Barrier in Health and Disease in Human.

Authors:  Anthony P Corfield
Journal:  Microorganisms       Date:  2018-08-02

6.  Akkermansia muciniphila ameliorates the age-related decline in colonic mucus thickness and attenuates immune activation in accelerated aging Ercc1 -/Δ7 mice.

Authors:  Benthe van der Lugt; Adriaan A van Beek; Steven Aalvink; Ben Meijer; Bruno Sovran; Wilbert P Vermeij; Renata M C Brandt; Willem M de Vos; Huub F J Savelkoul; Wilma T Steegenga; Clara Belzer
Journal:  Immun Ageing       Date:  2019-03-08       Impact factor: 6.400

Review 7.  Akkermansia muciniphila is a promising probiotic.

Authors:  Ting Zhang; Qianqian Li; Lei Cheng; Heena Buch; Faming Zhang
Journal:  Microb Biotechnol       Date:  2019-04-21       Impact factor: 5.813

8.  The Bacterium Akkermansia muciniphila: A Sentinel for Gut Permeability and Its Relevance to HIV-Related Inflammation.

Authors:  Jing Ouyang; John Lin; Stéphane Isnard; Brandon Fombuena; Xiaorong Peng; André Marette; Bertrand Routy; Meriem Messaoudene; Yaokai Chen; Jean-Pierre Routy
Journal:  Front Immunol       Date:  2020-04-09       Impact factor: 7.561

Review 9.  Function of Akkermansia muciniphila in Obesity: Interactions With Lipid Metabolism, Immune Response and Gut Systems.

Authors:  Yu Xu; Ning Wang; Hor-Yue Tan; Sha Li; Cheng Zhang; Yibin Feng
Journal:  Front Microbiol       Date:  2020-02-21       Impact factor: 5.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.